Aydin Senkut is the Founder and Managing Director of Felicis Ventures. An original “super-angel” investor, he was named to Forbes’ Midas List in 2014, 2015 and 2016, and to NY Times' Top 20 VCs list in 2016. Aydin is well-known as an early backer of a number of iconic companies including Shopify (NYSE:SHOP), Fitbit (NYSE:FIT), Adyen, Clearslide, Credit Karma, and Rovio. More than 60 Felicis companies such as Brightroll, Climate Corp, Dropcam, Twitch, and Meraki, have been acquired by industry leaders such as Google, Amazon, Cisco, Apple, Microsoft, AT&T, Disney, Yahoo and Ebay. His recent focus areas include re-invention of core markets like intelligent SaaS and financial services as well as development of frontier technologies including AI/deep learning and robotics. Prior to starting Felicis Ventures, Aydin was a Senior Manager at Google, responsible for strategic partner development and account management in Asia Pacific (including Japan). Aydin joined Google in 1999 as its first Product Manager to launch Google’s first 10 international sites, its first online search licensing products and its first Safe Search. He then became the first International Sales Manager at Google, responsible for world-wide licensing deals. Before joining Google, Aydin was the Product Manager for Data Visualization and Data Mining software MineSet at SGI. Aydin received a BS in Business Administration with Honors from Boston University. He also earned an MBA in Marketing from the Wharton School and an MA in International Studies from the School of Arts at the University of Pennsylvania. He speaks five languages: English, German, French, Portuguese and Turkish. Aydin and his wife are Associate Founders of Singularity University, have backed bio-tech research at UCSF and sponsored a scholarship at the University of Pennsylvania.Aydin has also been featured on Businessweek, New York Times, Wall Street Journal, Fortune, and Financial Times Germany.
Corey M McCann M.D., Ph.D. is the President and CEO of Pear Therapeutics, a company developing prescription digital therapeutics and drug/software combinations for treatment of severe medical conditions. Previously, he was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey’s central nervous system (CNS) expertise group, advising clients across the healthcare value chain. Corey has previous investment experience with RiverVest Venture Partners, where he performed diligence on early stage investments, and at NeuroInsights, where he evaluated brain related technologies. Corey is also a co-founder, advisor, or Board Director at AgNovos Healthcare, Alcyone Lifesciences, Dragonfly Sciences, Edumedics, Resolute Bio, Selexys Pharmaceuticals, and Zillion Health. Dr. McCann trained as a physician-scientist via the Medical Scientist Training Program. For his PhD, he studied the molecular biology of synapses at Harvard University and at Washington University in St Louis. He was also a post-doctoral researcher at the Massachusetts General Hospital where he developed imaging techniques for the visualization of the brain. Dr. McCann received his M.D. from Washington University in St. Louis. He graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar, receiving a B.S. in Biology with minors in neuroscience, biochemistry, and molecular biology.